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Tardive dyskinesia (TD) is a hyperkinetic movement disorder associated with the prolonged use of antipsychotic drugs. Since prostate 
apoptosis response 4 (Par-4) is a key ligand of the dopamine D2 receptor, the Par-4 gene (PAWR) is a good candidate gene to study in the 
context of TD susceptibility. We examined the association between PAWR gene polymorphisms and TD. Three single nucleotide poly-
morphisms of PAWR were selected for the analysis: rs7979987, rs4842318, and rs17005769. Two hundred and eighty unrelated Korean 
schizophrenic patients participated in this study (105 TD and 175 non-TD patients). Genotype/allele-wise and haplotype-wise analyses 
were performed. There were no significant differences in genotype and allele frequencies between the two groups. Haplotype analysis also 
did not reveal a difference between the two groups. Within the limitations imposed by the size of the clinical sample, these findings sug-
gest that PAWR gene variants do not significantly contribute to an increased risk of TD.           Psychiatry Investig 2012;9:191-194
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INTRODUCTION
Tardive dyskinesia (TD) is a hyperkinetic movement disor-
der associated with the prolonged use of antipsychotic drugs.
1 
The annual incidence was reported to be 3.9% for second-
generation antipsychotics and 5.5% for first-generation anti-
psychotics, while the prevalence is 13.1% for second-genera-
tion antipsychotics, 15.6% for antipsychotic-free patients, and 
32.4% for first-generation antipsychotics.
2 Although hypothe-
ses such as dopamine receptor supersensitivity, imbalance be-
tween D1 and D2 receptor-mediated effects and the GABA 
hypothesis have been suggested, the pathophysiology of TD is 
not well defined.
1,3-9 Among the risk factors known for TD, 
age is the most robust.
10-13 Other risk factors include non-
white ethnicity, extrapyramidal symptoms, lack of response to 
treatment, worse premorbid functioning, negative symptoms, 
long treatment duration, worsening of psychosis and prolac-
tine-related sexual dysfunction.
14
Genetic susceptibility has been also examined in many stu-
dies. There have been substantial case-control association 
studies on TD, and a number of studies have been conducted 
on the genes involved in drug metabolism such as cyto-
chrome P450 (CYP), monoamine receptor genes, and oxida-
tive stress related genes. As a result, relatively consistent find-
ings have been reported for certain polymorphisms such as 
CYP2D6*10,
15 dopamine D2 receptor (DRD2) Taq1A,
16 do-
pamine D3 receptor (DRD3) Ser9Gly,
17 serotonin 2A receptor 
(HTR2A) T102C,
18 and manganese superoxide dismutase 
(MnSOD) Ala9Val,
19,20 though they are still controversial. 
Recently, Park et al.
21 identified prostate apoptosis response 
4 (Par-4) as a regulatory component in dopamine signaling. 
In their model of the involvement of Par-4 in the regulation of 
DRD2 signaling, Par-4/DRD2 complex formation via the 
calmodulin binding motif in the third cytoplasmic loop was 
suggested to inhibit cAMP signaling from DRD2. Moreover, 
they also observed that a mutant mouse lacking the DRD2 
interaction domain of Par-4 displayed depression-like behav-
iors.192  Psychiatry Investig 2012;9:191-194
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Since TD mainly develops in patients treated with a DRD2 
blocker, the Par-4 gene (PAWR) could be associated with TD. 
In this study, we selected three SNPs of PAWR and examined 
their association with TD susceptibility in Korean schizo-
phrenia patients.
METHODS
Subjects and assessment
All subjects were ethnically homogeneous Korean and were 
examined by trained psychiatrists using the Korean version of 
the Structured Clinical Interview for DSM-IV, leading to a di-
agnosis based on DSM-IV criteria.
22 Written informed con-
sent was obtained from each patient, and the study protocol 
was approved by the Ethics Committee of the Korea Univer-
sity Medical Center. None of the patients had a significant co-
morbid neurological illness, mental retardation, or history of 
substance abuse. All subjects were inpatients at collaborating 
hospitals of Korea University. Other findings from these sub-
jects have been reported previously.
20,23-28
Assessment with the Abnormal Involuntary Movement 
Scale (AIMS)
29 was used to recruit 105 schizophrenic patients 
with TD and 175 schizophrenic patients without TD. Our test 
sample included TD patients who had received atypical anti-
psychotic treatment (25 patients), which reportedly has a 
lower risk of TD than typical antipsychotic treatment, and 
who had been treated for less than ten years (18 patients). All 
of the non-TD patients in the test sample had received typical 
antipsychotic treatment for at least ten years. We applied these 
different inclusion criteria since the occurrence of TD in pa-
tients treated for less than ten years is indicative of a higher 
genetic susceptibility. Their current antipsychotic dosages 
were converted into chlorpromazine equivalents. All patients 
were maintained on stable dosages of antipsychotics for at 
least three&#160;months before the assessment of TD. The 
TD diagnosis was performed according to the Research Diag-
nostic Criteria for TD (RDC-TD) on the basis of AIMS.
30 We 
rated the first seven items of the AIMS to determine the total 
AIMS score of abnormal movements in the patients. Subjects 
with two or more two-point ratings or one or more three-
point ratings on the first seven items of the AIMS were diag-
nosed with TD according to RDC-TD. Clinical symptoms 
were measured by the Positive and Negative Syndrome Scale 
(PANSS).
31
Genetic markers
Three single nucleotide polymorphisms (SNPs) were se-
lected for the analysis: rs7979987, rs4842318, and rs17005769. 
To evaluate the coverage rate of the three SNPs for the total 
PAWR gene variation we consulted the HapMap database 
(release #27, population: CHB, http://hapmap.ncbi.nlm.nih.
gov). There were 41 SNPs reported to have a minimal allele 
frequency of more than 0.1. We performed 2- and 3- marker 
aggressive tagging using the Tagger program implemented in 
Haploview 4.2 (http://www.broadinstitute.org/haploview). 
We found that 35 of 41 (85%) SNPs were captured by the 
three SNPs.
Genotyping
Blood samples (5-10 mL) from subjects were collected in 
EDTA, and genomic DNA was isolated using a NucleoSpin
Ⓡ 
Blood DNA Extraction Kit (Macherey-Nagel, Germany) ac-
cording to the manual. Genotyping was performed by high-
resolution melting (HRM) curve analysis. PCR was per-
formed in a volume of 20 μL per reaction with a 96-well Bio-
Rad CFX96 Real Time PCR System (Bio-Rad, Hercules, CA, 
USA). Reaction mixtures included 1.5 μL of genomic DNA as 
template, 200 mM of each primer [rs7979987-F: GGA CAT 
TAT CTC TGG GTT AG, rs7979987-R: ACA TAA GCA 
CAT ACA CCA AC, rs4842318-F: GAA GGC TAC ACG 
CTA CAT T, rs4842318-R: AGA TGA GTC TGA AGG TCC 
AAT A, rs17005769-F: TCT ACA ATC TGT CCT TAG AAA 
CTT AA, rs17005769-R: CTT TCA AGG TTG TTA ATG 
GCA TAA] (BMS, Daejeon, Korea), 1×Sso Fast EvaGreen Su-
perMix (Bio-Rad), and sterile H2O. The amplification proto-
col started with 98°C/3 min followed by 39 cycles of 98°C/10 s 
and 58°C/20 s. After an initial step of 95°C/10 s and 65°C/10 s, 
melting curves were generated from 65°C to 95°C in incre-
ments of 0.3°C/cycle. Melting profiles were analyzed with the 
Bio-Rad Precision Melt Software.
Statistical analysis
Differences between categorical and continuous variables 
were evaluated by the chi-square test and Student’s t-test, re-
spectively. The total PANSS and AIMS scores were evaluated 
by ANCOVA with sex, age, duration of antipsychotics and 
smoking status as covariates. Genotype deviation from Har-
dy-Weinberg equilibrium (HWE) was evaluated by the chi-
square test for goodness of fit. Haplotype analysis was per-
formed using the UNPHASED 3.1.4 software.
32 A power 
calculation was performed using G*Power3.1.3.
33 The cutoff 
p-value was set at 0.05.
RESULTS
There were significant differences in age (non-TD: 43.47± 
9.174 years; TD: 46.29±9.722 years, p=0.016) and smoking 
status of female subjects (non-TD: smoker/nonsmoker= 
18/64, TD: smoker/nonsmoker=21/27, p=0.009), while no sig-
nificant differences were observed between groups with re-IS Kim et al. 
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gard to sex, duration of illness, duration of antipsychotic 
treatment, current antipsychotic dosage and smoking status. 
Total AIMS scores (mean±SD) were higher in TD subjects 
(non-TD: 0.74±1.062 vs. TD: 7.66±4.287, p=0.010). Total 
PANSS scores were not significantly different (non-TD: 87.87± 
18.77 vs. TD: 92.43±19.49, p=0.095) although the general 
PANSS subscores were higher in TD patients than in non-TD 
patients (non-TD: 42.87±9.80 vs. TD: 46.29±11.07, p=0.010). 
Genotype frequencies of all SNPs were in Hardy-Weinberg 
equilibrium. There were no significant differences in geno-
type or allele frequencies between the two groups (Table 1). 
Haplotype analysis also detected no significant difference be-
tween the two groups in either two- (data not shown) or three-
marker haplotypes (Table 2).
DISCUSSION
Prostate apoptosis response-4 (Par-4) is a key ligand of 
DRD2. Par-4 is expressed in the striatal neurons along with 
DRD2 and interacts with DRD2 in neural cells.
34 Par-4 nor-
mally enhances DRD2 signaling and thereby inhibits dopa-
mine/DRD2-mediated neurotransmission.
21 Par-4 specifically 
interacts with DRD2 via its leucine domain, and it can be co-
immunoprecipitated with DRD2 in mouse brain lysate. Once 
DRD2 is activated, Par-4/DRD2 complex formation is neces-
sary for the maintenance of inhibitory tone in dopamine-me-
diated cAMP signaling. The binding of Par-4 to DRD2 regu-
lates cAMP signaling, and subsequently affects the function 
of the DA-cAMP-CREB pathway.
21 Therefore, Par-4 (PAWR) 
is a good candidate gene to study in the context of TD.
However, in this study, the three PAWR SNPs we analyzed 
were not associated with TD in terms of genotype, allele, or 
haplotype. These findings indicate that PAWR may not relat-
ed to TD susceptibility. However, it is still possible that other 
regions of the PAWR gene are associated with TD. The stud-
ied SNPs only captured approximately 85% of the genetic 
variations in the PAWR gene according to the HapMap data-
base. On the other hand, it is also possible that the regulatory 
regions outside of the PAWR gene are associated with TD. 
The negative association of the analyzed SNPs could be due to 
type II error. The power was 0.86 and 0.92 to detect an effect 
size of 0.20 in the analysis of genotype and allele frequencies, 
respectively. There are additional limitations to generalization 
of the results of this study. Although anticholinergics and 
benzodiazepines had been reported to be beneficial in some 
cases of TD, we could not control these drugs. There was sig-
nificant age difference between the TD and non-TD group, 
although we tried to control the age as a covariate in some 
analyses. Recently, Liou et al.
35 tested whether variation in the 
PAWR gene might be related to TD susceptibility with five 
SNPs as genetic markers: rs1705769, rs7305141, rs8176874, 
rs7955388 and rs2307220. However, their results did not indi-
cate any association between PAWR genetic polymorphisms 
and TD. Our finding supports their results. In conclusion, we 
Table 2. Haplotype analysis for PAWR between TD and non-TD subjects
Haplotype
Overall p value
Haplotype frequencies
p value
(rs7979987, rs4842318, rs17005769) Non-TD TD
C-C-T
0.80 
0.229  0.189  0.300 
C-T-T 0.000  0.006  0.378 
G-C-C 0.241  0.256  0.718 
G-C-T 0.194  0.203  0.815 
G-T-C 0.008  0.006  0.968 
G-T-T 0.329  0.340  0.771 
TD: tardive dyskinesia
Table 1. PAWR Genotype and allele distributions between TD and non-TD subjects
SNP ID Position
Allele
Phenotype
Genotype Allele p value
1/2 1/1 1/2 2/2 1 2 Genotype Allele HWE
rs7979987 78522768 G/C Non-TD 103 64 8 0.7714 0.2286 0.469  0.354  0.953 
TD 66 37 2 0.8048 0.1952 0.630 
rs4842318 78568298 C/T Non-TD 70 92 13 0.6629 0.3371 0.660  0.713  0.226 
TD 42 52 11 0.6476 0.3524 0.830 
rs17005769 78579258 T/C Non-TD 94 75 6 0.7514 0.2486 0.651  0.726  0.314 
TD 56 43 6 0.7381 0.2619 0.935 
TD: tardive dskinesia, HWE: Hardy-Weinberg Equilibrium, SNP: single nuclotide polymorphism194  Psychiatry Investig 2012;9:191-194
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did not identify any association between three PAWR SNPs 
and TD in Korean schizophrenia patients. However, further 
studies with a larger sample size and more genetic markers 
will be necessary to confirm these results.
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